Sandoz used its Capital Markets Day in London to introduce Bio100, a new long‑term strategy for the company’s biosimilar business.
The plan calls for the biosimilar portfolio to grow from the current 13 approved products to more than 100 by 2040. At the same time, Sandoz reaffirmed the financial outlook it previously set for the period through 2028.
A central element of Bio100 is a target EBITDA margin of 30% for the biosimilar segment. Management indicated that revenue growth will be “significant” over the coming years, although no specific growth rates were disclosed.
To reach these goals, Sandoz intends to invest in product development, expand manufacturing capacity and strengthen market access, positioning itself to capture a larger share of the expanding global demand for affordable biologic therapies.
The Swiss drugmaker, the generic and biosimilar arm of Novartis, said the 2028 outlook remains unchanged, reflecting confidence in its pipeline and market positioning.
The announcement did not include any changes to dividend policy or share‑repurchase programmes.
